Research
What a drug advertisement is not allowed to do
Federal regulation lists, one by one, the ways an advertisement for a prescription drug can mislead. The list reads like an inventory of the moves you see every day on a product page.
A published list of prohibited moves
Advertising rules are usually written as principles. One rule about prescription drug advertising is written as a catalog instead, naming specific presentation tricks and prohibiting each by name.
That makes it unusually useful to a reader. You do not have to reason from a general standard about deception. You can compare a page against a list.
The regulation covers advertisements in journals, magazines, periodicals and newspapers, and broadcasts through radio, television and telephone communication systems.
Whether any particular seller's page is an advertisement subject to that section is a legal question, and one this site does not answer. What follows is the standard itself, which is worth reading either way.
Fair balance, defined
The core requirement is a brief summary of side effects, contraindications and effectiveness. The regulation then explains when that summary fails.
It fails if it "is false or misleading with respect to side effects, contraindications, or effectiveness." That much is expected.
The second failure is the interesting one. An advertisement fails if effectiveness information "is presented in greater scope, depth, or detail" than the statute requires while risk information is not fairly balanced against it.
A proviso then supplies the test in a form you can apply by eye. No advertisement violates the section where risk information "is comparable in depth and detail with the claims for effectiveness or safety."
The duty to reveal what changes the picture
A third failure mode is broader than the first two and easy to overlook.
An advertisement also fails if it "fails to reveal facts material in the light of its representations." The same clause covers facts material to consequences that may result from using the drug as the advertisement recommends.
That is a duty about omission rather than assertion. Nothing in the advertisement has to be untrue for it to fail this test.
It is also self-referencing. What counts as material depends on the claims the advertisement itself chose to make, so a bolder page owes more disclosure than a modest one.
Where the evidence rules are written as advertising rules
Then comes the catalog. Several entries describe reasoning failures that this site covers elsewhere, and it is striking to find them written as regulation.
Animal and laboratory data get their own entry. An advertisement is misleading if it contains favorable data or conclusions from nonclinical studies. The prohibited use is presenting them "such as in laboratory animals or in vitro, in a way that suggests they have clinical significance when in fact no such clinical significance has been demonstrated."
So does overstating what one study covered. It is misleading to present "information from a study in a way that implies that the study represents larger or more general experience with the drug than it actually does."
And so does a familiar statistical move. The entry begins "Uses erroneously a statistical finding of" and then names the finding. The prohibited use of it is "to claim clinical equivalence or to deny or conceal the potential existence of a real clinical difference."
How citations are allowed to be used
Four entries in the list are about references, and together they describe most of what goes wrong with a citation list on a product page.
A quotation may not be used "out of context to convey a false or misleading idea."
References may not be used that "purport to support an advertising claim but in fact do not support the claim or have relevance to the claim." Nor may they be used to recommend or suggest conditions of use that are not in the approved labeling.
And a favorable expert statement carries a duty to keep reading. An advertisement is misleading if it uses an apparently favorable statement by a recognized authority. The failure named is where it "fails to refer to concurrent or more recent unfavorable data or statements from the same authority on the same subject or subjects."
Selection, pooling and normal volunteers
Three more entries concern how a body of evidence is assembled rather than how one study is read.
Selective presentation is named directly. It is misleading to suggest a drug is safer than shown by selecting from published articles that report no or minimal side effects. The same applies to selecting information from any source "in a way that makes a drug appear to be safer than has been demonstrated."
Pooling gets its own entry. Counts of patients or of favorable results may not be derived from pooling data "from various insignificant or dissimilar studies." The prohibition bites where that suggests the resulting figures are valid, or come from large studies, when they do not.
And healthy volunteers must be disclosed as such. An advertisement is misleading if it "Uses a study on normal individuals without disclosing that the subjects were normal," unless the drug is meant for normal individuals.
Comparisons, potency and dose
The last group covers claims made against something else, which is the shape most comparison marketing takes.
A comparison is misleading where it suggests a drug "is safer or more effective than another drug in some particular." That is the rule where it "has not been demonstrated to be safer or more effective in such particular."
Claims about composition and strength are covered too. Saying a drug differs from a named drug, or has greater potency per unit of weight, is misleading where it falsely suggests the advertised drug is safer or more effective.
And dose matters. Data from patients treated at dosages different from those in approved labeling may not be used favorably, subject to the section's own qualifications about which drugs that applies to.
Two cautions about using this list
This is a genuinely useful checklist, and two things keep it honest.
The first is scope. These rules attach to advertisements for prescription drugs, and a page that is not one is not covered by them. What the list gives a reader is a published, official statement of which presentation moves an agency treats as misleading, which is worth having whether or not a specific page is inside its reach.
The second is a reading trap in the regulation itself. The section prints two versions of two of its paragraphs, because a 1979 revision to them was stayed indefinitely and the stayed text is reproduced at the bottom for convenience.
Anyone quoting from this section by searching for a phrase can land in that note and quote a rule that never came into force. The operative text is the one in the body of the section.
Key takeaways
- Prescription drug advertising rules are written as a catalog of named, prohibited moves.
- Fair balance is tested by whether risk information is comparable in depth and detail to the claims.
- An advertisement can fail purely by omitting facts material to the claims it chose to make.
- Presenting nonclinical or animal data as clinically significant is named as misleading.
- Quoting out of context, and citing references that do not support the claim, are both named.
- Pooling dissimilar studies and misusing "no significant difference" are both named.
- The section reprints two stayed paragraphs at the end, and that text never took effect.
Frequently asked questions
What does fair balance mean?
The regulation defines it by its failure. An advertisement fails to present a true statement if effectiveness information is presented in greater scope, depth or detail than the statute requires. The failure completes where that is not fairly balanced by a summary of true information on side effects and contraindications. It then supplies a proviso: no advertisement violates the section where the presentation of true risk information is comparable in depth and detail with the claims for effectiveness or safety. That is a comparison of how much space and detail each side gets.
Does an advertisement have to be untrue to break these rules?
No. One of the three named failures is a failure to reveal facts material in the light of the advertisement's own representations, or material to consequences that may result from using the drug as recommended. That is a duty about omission. It also scales with the claims made, because what counts as material depends on what the advertisement asserted in the first place, so a stronger claim carries a heavier disclosure duty.
What does the regulation say about animal and laboratory data?
It names them. An advertisement is misleading where it contains favorable data or conclusions from nonclinical studies, such as in laboratory animals or in vitro. The prohibited use is presenting them in a way that suggests clinical significance where none has been demonstrated. The reasoning behind why laboratory results do not carry to people is covered separately on this site. What is notable here is that the same failure appears in a federal regulation as prohibited advertising conduct.
Are there rules about how studies can be cited?
Several. A quotation may not be used out of context to convey a false or misleading idea. References may not be used that purport to support a claim but do not support it or are not relevant to it. They may also not be used to suggest uses that are not in approved labeling. A favorable statement from a recognized authority is misleading where the advertisement fails to refer to concurrent or more recent unfavorable data or statements from that same authority on the same subject.
Do these rules apply to a compounded peptide seller's website?
That is a legal question about a specific business and a specific page, and this site does not decide it. The rules are written for advertisements for prescription drugs, and the regulation lists the media it covers. What the list is useful for regardless is as a published standard: it names, one by one, the presentation techniques an agency treats as misleading about a medicine. Reading a page against that list tells you something whether or not the page is formally within scope.
Why does the section print some paragraphs twice?
Because a revision to two of them was stayed. The section carries an effective date note recording that a 1979 revision of two paragraphs was stayed indefinitely, and it reproduces that stayed text at the bottom for the convenience of the user. The wording differs from the operative version. Anyone searching the section for a phrase can land in the note and quote a rule that never took effect, so the text in the body of the section is the one that governs.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- Title 21 Code of Federal Regulations section 202.1, Prescription-drug advertisements — the brief summary requirement at (e)(1), the definition of a true statement and fair balance at (e)(5), the enumerated grounds on which an advertisement is false, lacking in fair balance or otherwise misleading at (e)(6)(i) through (xvii), the media covered at (l)(1), and the effective date note recording that the 1979 revision of paragraphs (e)(6)(ii) and (vii) was stayed indefinitely — Electronic Code of Federal Regulations, Office of the Federal Register, November 2023